DGAT1 — Diacylglycerol O-Acyltransferase 1

DGAT1 — Diacylglycerol O-Acyltransferase 1

Introduction

The DGAT1 gene (Diacylglycerol O-Acyltransferase 1) encodes an essential enzyme responsible for the final step in triglyceride synthesis, catalyzing the acyl-CoA-dependent acylation of diacylglycerol to form triacylglycerol (TAG). DGAT1 belongs to the acyltransferase family and plays a critical role in lipid metabolism throughout the body. While traditionally studied in the context of metabolic diseases such as obesity and insulin resistance, emerging research reveals that DGAT1 also plays important roles in the central nervous system (CNS), particularly in [neurons](/entities/neurons) where lipid homeostasis is essential for synaptic function, membrane integrity, and neuronal survival[@cases2001][@buono2006].

Dysregulation of neuronal lipid metabolism has been increasingly recognized as a contributing factor in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD). DGAT1-mediated triglyceride synthesis and lipid droplet formation in neurons may influence amyloid-beta (Aβ) aggregation, tau phosphorylation, and α-synuclein pathology. Consequently, DGAT1 has emerged as a potential therapeutic target for neurodegenerative disease modification[@chen2013][@chan2016].

DGAT1 — Diacylglycerol O-Acyltransferase 1

Introduction

The DGAT1 gene (Diacylglycerol O-Acyltransferase 1) encodes an essential enzyme responsible for the final step in triglyceride synthesis, catalyzing the acyl-CoA-dependent acylation of diacylglycerol to form triacylglycerol (TAG). DGAT1 belongs to the acyltransferase family and plays a critical role in lipid metabolism throughout the body. While traditionally studied in the context of metabolic diseases such as obesity and insulin resistance, emerging research reveals that DGAT1 also plays important roles in the central nervous system (CNS), particularly in [neurons](/entities/neurons) where lipid homeostasis is essential for synaptic function, membrane integrity, and neuronal survival[@cases2001][@buono2006].

Dysregulation of neuronal lipid metabolism has been increasingly recognized as a contributing factor in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD). DGAT1-mediated triglyceride synthesis and lipid droplet formation in neurons may influence amyloid-beta (Aβ) aggregation, tau phosphorylation, and α-synuclein pathology. Consequently, DGAT1 has emerged as a potential therapeutic target for neurodegenerative disease modification[@chen2013][@chan2016].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Diacylglycerol O-Acyltransferase 1</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>DGAT1</td></tr>
<tr><td><strong>Full Name</strong></td><td>Diacylglycerol O-Acyltransferase 1</td></tr>
<tr><td><strong>Chromosome</strong></td><td>8q24.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[8694](https://www.ncbi.nlm.nih.gov/gene/8694)</td></tr>
<tr><td><strong>OMIM</strong></td><td>604035</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000185088</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9H5Z1](https://www.uniprot.org/uniprot/Q9H5Z1)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Metabolic Syndrome, Obesity, Lipid Storage Disorders</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The DGAT1 gene is located on chromosome 8q24.3 and spans approximately 16 kilobases. It consists of 17 exons that encode a protein of approximately 460 amino acids.

| Property | Value |
|----------|-------|
| Gene Symbol | DGAT1 |
| Chromosomal Location | 8q24.3 |
| NCBI Gene ID | 8694 |
| Ensembl ID | ENSG00000185088 |
| UniProt | Q9H5Z1 |
| RefSeq | NM_001122998 |

Protein Structure

The DGAT1 protein contains several key structural features:

DGAT1 localizes primarily to the ER membrane, where it accesses its substrates in the ER lumen and cytosol. It can also associate with lipid droplets under certain conditions[@buono2006][@liu2012].

Normal Biological Functions

Triglyceride Synthesis

DGAT1 catalyzes the final and committed step in triglyceride biosynthesis:

Diacylglycerol + Acyl-CoA → Triacylglycerol + CoA

This reaction sequesters fatty acids in theirStorage form (triglycerides) within lipid droplets, protecting cells from lipotoxicity associated with excess free fatty acids.

Lipid Droplet Formation

DGAT1 plays a critical role in lipid droplet biogenesis:

In non-adipose tissues, including the brain, lipid droplets serve important functions in buffering lipid species and providing energy during stress[@zhang2018].

Neuronal Lipid Metabolism

In neurons, DGAT1 and lipid droplets serve several essential functions:

• Membrane Synthesis: TAGs provide fatty acids for phospholipid synthesis
• Energy Storage: Lipid droplets fuel neuronal metabolism during high activity
• Lipotoxicity Prevention: Sequestering excess fatty acids protects against ER stress
• Synaptic Function: Lipid composition affects synaptic vesicle dynamics and neurotransmitter release

Expression Pattern in the Central Nervous System

Cellular Distribution

DGAT1 is expressed in multiple cell types within the CNS:

• Neurons: Moderate expression in most neuronal populations
• Astrocytes: Higher expression; major contributors to brain lipid metabolism
• Oligodendrocytes: Essential for myelin lipid synthesis
• Microglia: Lower expression; involvement in lipid clearance

Regional Expression

High expression is observed in:

• Cerebral cortex
• Hippocampus (particularly CA3 region)
• Cerebellum (Purkinje cells)
• Basal ganglia
• Substantia nigra (dopaminergic neurons)

Disease Associations

Alzheimer's Disease

DGAT1 is implicated in AD through multiple mechanisms:

Amyloid Metabolism: Altered lipid metabolism affects amyloid precursor protein (APP) processing and Aβ secretion. DGAT1 inhibition reduces Aβ production in cellular models, suggesting that TAG synthesis may influence amyloidogenic processing[@chen2013].

Lipid Droplet Accumulation: Post-mortem AD brain shows increased lipid droplet accumulation in neurons and glia. DGAT1-mediated TAG synthesis contributes to this accumulation, which may impair cellular function and promote neurodegeneration[@zhang2018].

Synaptic Dysfunction: Neuronal lipid metabolism is essential for synaptic vesicle cycling and neurotransmitter release. DGAT1 deficiency or inhibition disrupts these processes, potentially contributing to synaptic loss in AD[@li2020].

Therapeutic Potential: DGAT1 inhibitors reduce Aβ toxicity in vitro and improve cognitive function in AD mouse models. These findings support continued investigation of DGAT1 as a therapeutic target[@zhao2019][@rodriguez2021].

Parkinson's Disease

DGAT1 contributes to PD pathophysiology:

α-Synuclein Pathology: Lipid droplets interact with α-synuclein and may influence its aggregation. DGAT1-mediated lipid droplet formation may either protect against or promote α-synuclein pathology depending on context[@villanueva2019].

Dopaminergic Neuron Vulnerability: The substantia nigra has high lipid metabolic demands due to ongoing dopamine synthesis. DGAT1-mediated lipid homeostasis is essential for maintaining dopaminergic neuron health.

Oxidative Stress: Lipid droplets serve as both sinks and sources of oxidative stress. DGAT1 inhibition reduces oxidative damage in neuronal models, potentially through altered lipid droplet dynamics[@yang2020].

Metabolic Disease

Beyond neurodegeneration, DGAT1 is central to systemic metabolic disease:

Obesity: DGAT1 deficiency or inhibition reduces adiposity in mouse models Insulin Resistance: Altered TAG metabolism affects insulin signaling Fatty Liver: DGAT1 inhibition reduces hepatic steatosis

These metabolic effects may indirectly influence neurodegeneration through altered systemic inflammation and cardiovascular health.

Molecular Mechanisms

Interaction with Lipid Pathways

DGAT1 intersects with multiple lipid metabolic pathways:

| Pathway | Interaction |
|---------|-------------|
| Fatty Acid Synthesis | Provides substrates for TAG synthesis |
| Phospholipid Synthesis | Competes for DAG precursors |
| Cholesterol Esterification | Shares substrates (DAG) |
| Ceramide Synthesis | Cross-talk with sphingolipid pathways |
| Autophagy | Lipid droplets are targets of lipophagy |

Transcriptional Regulation

DGAT1 expression is regulated by several transcription factors:

• SREBP1: Sterol regulatory element-binding protein 1 activates DGAT1 transcription
• PPARγ: Peroxisome proliferator-activated receptor gamma induces DGAT1 expression
• LXR: Liver X receptors modulate DGAT1 in response to cholesterol levels
• XBP1: X-box binding protein 1 regulates DGAT1 during ER stress

Post-Translational Regulation

DGAT1 activity is modulated by:

• Phosphorylation: Multiple serine/threonine sites affect activity
• Acetylation: Lysine acetylation modulates enzyme function
• Sumoylation: SUMO modification affects subcellular localization
• Protein-protein interactions: DGAT1 forms homodimers and heterodimers with DGAT2

Therapeutic Implications

DGAT1 Inhibitors

Several DGAT1 inhibitors have been developed for metabolic disease and are being repurposed for neurodegeneration:

| Compound | Target | Stage | Key Findings |
|----------|--------|-------|--------------|
| T863 | DGAT1 | Preclinical | Reduces Aβ toxicity[@zhao2019] |
| JNJ-37619832 | DGAT1 | Research | Improves cognitive function |
| PF-04620110 | DGAT1 | Clinical (obesity) | Well-tolerated in humans |

Challenges in CNS Drug Development

Developing DGAT1-targeted therapies for neurodegenerative diseases presents several challenges:

Alternative Strategies

• Brain-penetrant DGAT1 inhibitors: Developing compounds with improved CNS penetration
• Allosteric modulators: Targeting specific protein conformations
• Gene therapy: AAV-mediated knockdown in specific brain regions
• Combination therapy: Targeting DGAT1 with other metabolic pathways

Animal Models

Genetic Models

• Dgat1 knockout mice: Viable but display reduced adiposity and resistance to diet-induced obesity
• Neuron-specific KO: Reveals neuronal functions of DGAT1
• Conditional models: Temporal control of DGAT1 deletion

Disease Models

• APP/PS1 mice: DGAT1 inhibition reduces amyloid burden
• 5xFAD mice: Improved cognitive function with DGAT1 inhibition
• α-Synuclein transgenic mice: Variable effects on pathology

Phenotype Studies

• Learning and memory: DGAT1 deficiency impairs memory consolidation
• Motor function: Altered motor coordination in some models
• Metabolism: Improved systemic glucose tolerance

Research Directions

Emerging Areas

• Spatial lipidomics: Mapping lipid species in specific brain regions
• Single-cell analysis: Characterizing DGAT1 in distinct neuronal populations
• Proteomics: Identifying DGAT1 interaction partners in the brain
• Biomarkers: Developing blood-based markers of neuronal lipid status

Clinical Translation

Several factors favor DGAT1 as a therapeutic target:

• Well-characterized biochemistry and pharmacology
• Existing clinical data from metabolic disease trials
• Clear mechanism linking lipid metabolism to neurodegeneration
• Measurable endpoints (lipid profiles, cognitive testing)

Unresolved Questions

• Optimal timing of intervention (preventive vs. treatment)
• Duration of therapy required for disease modification
• Combination with other therapeutic approaches
• Patient stratification based on lipid metabolism status

Cross-Links

• [Lipid Metabolism](/mechanisms/lipid-metabolism)
• [Neuronal Lipid Homeostasis](/mechanisms/neuronal-lipid-homeostasis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Lipid Droplets in Neurodegeneration](/mechanisms/lipid-droplets)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving dgat1 discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving DGAT1 — Diacylglycerol O-Acyltransferase 1 discovered through SciDEX knowledge graph analysis: